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Abstract: The incidence of post transplant viral infections has increased with the use of more potent immunosuppressive
regimens. Consequently, BK virus nephropathy (BKVN) has arisen as a significant cause of graft dysfunction and loss.
Reduction of immunosuppression is the first line management of post-transplant viral infections. Other therapies such as
intravenous immunoglobulin (IVIg), cidofovir, leflunomide and fluoroquinolones have been tried with varying degrees of
success.
We report our experience with IVIg in three pediatric renal transplant recipients who presented with allograft dysfunction.
First, we describe two cases of biopsy proven BKVN, one diagnosed with undetectable viral titers in plasma,
demonstrating that BKVN can occur even at low viral loads. We also present a pediatric renal transplant recipient with
persistent BK viremia and allograft dysfunction who responded to therapy with recovery of renal function and clearance
of viremia. Therefore we conclude that IVIg is efficacious in the treatment of persistent BK viremia and BKVN. The
appropriate dose, frequency and duration of therapy require further study.

Keywords: Allograft dysfunction, BK viremia, BK virus nephropathy (BKVN), immunosuppression reduction, intravenous
immunoglobulin (IVIg), pediatric transplantation.
INTRODUCTION
BK virus nephropathy (BKVN) has become of significant
concern as a cause of graft dysfunction and loss in the renal
transplant population. Dormant BK virus is reactivated in the
setting of increased immunosuppression, causing tubulointerstitial nephritis in up to 8% of patients [1]. Presently no
standard therapy for BK viremia and nephropathy has been
established.
Reduction in immunosuppression is accepted as the first
line therapy in the management of BKVN [2]. The use of
leflunomide, cidofovir, IVIg and fluoquinolones as adjunct
therapy in addition to immunosuppression reduction in the
management of BK virus nephropathy has been evaluated in
several small clinical studies [3-6]. There have however been
no prospective randomized studies to compare the various
agents and provide much needed information on long-term
benefits.
Human intravenous immunoglobulin has immunomodulatory properties and has been used successfully for
transplant related indications including treatment of antibody
mediated rejection; desensitization of highly sensitized
transplant recipients and in treatment of post-transplant
infectious complications like parvovirus B19, cytomegalovirus and BKVN [7].
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One of the authors, Anyaegbu et al., has previously
reported her experience using IVIg for treatment of
persistent BK viremia and BK nephropathy [4]. There have
been conflicting reports on the efficacy of IVIg in the
treatment of BKVN. Majority of the reports have described
successful use in the management of BKVN. However there
have been reports of an increase in BK viral load following
IVIg therapy [8, 9].
We conducted a retrospective review at the Washington
University in St Louis of pediatric renal transplant recipients
who received IVIg therapy for management of BKVN and
report our successful treatment of BK viremia and
nephropathy with immunosuppression reduction and
administration of IVIg. Patients were screened for BK virus
when they presented with elevations in serum creatinine.
This was before the implementation of our prospective
screening protocol for BK viriuria and viremia. Our first line
strategy for management of BK viremia was
immunosuppression reduction, which was sufficient therapy
in the majority of patients. Three patients were diagnosed
with BKVN and received IVIg following an inadequate
response to only immunosuppression reduction. The
therapeutic benefit of IVIg after an insufficient response to
immunosuppression reduction was demonstrated in these
patients. Our report shows that administration of IVIg is an
effective option for the management of BKVN.
CASE 1
A 15-year-old Caucasian male with end stage renal
disease secondary to complications of William’s syndrome
received a renal transplant from a cadaveric donor. At the
2014 Bentham Open
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time of transplantation both the donor and recipient were
positive for cytomegalovirus. Induction agents included 5
doses of rabbit Thymoglobulin and pulse steroids that were
rapidly tapered. There was excellent graft function with rapid
decline in serum creatinine. He was maintained on a steroid
free regimen consisting of tacrolimus and mycophenolate
mofetil. Ureteral stents were removed 1 month after
transplant and graft function remained stable at a baseline of
0.7- 0.9 mg/dl.
Two years post-transplant, his serum creatinine increased
to 1.5 mg/dl. BK viremia was confirmed by quantitative
detection of BK virus in plasma. BK viral titers in urine and
plasma at diagnosis were greater than 1 X 106 copies and
1.39 X 106 respectively. An allograft biopsy showed diffuse
tubulointerstitial inflammation and a positive stain for
Simian virus 40 (SV-40) large T-antigen. C4d staining was
negative. His mycophenolate mofetil was discontinued and
his tacrolimus dose was reduced to 1mg twice a day
targeting tacrolimus troughs of 3- 4 ng/ml. There was an
inadequate response to reduction in immunosuppression,
which prompted administration of IVIg. He received 6 doses
of IVIg (0.5 g/kg) monthly with clearance of viremia and
improvement in allograft function.
CASE 2
A second patient was diagnosed with BKVN by biopsy.
He was found to have nephropathy in the setting of only BK
viruria and negative BK in plasma 77 days post transplant.
Urine viral titers were 3.23 X 106 with undetectable BK titers
in plasma. He received a heart transplant as an infant and
subsequently developed end stage renal disease from
cyclosporine nephrotoxicity. He received a living related
kidney from his mother. Induction	
   immunosuppression	
  
consisted	
   of	
   rabbit Thymoglobulin 1.5	
   mg/kg/dose	
   given	
  
daily	
   for	
   a	
   total	
   of	
   5	
   doses	
   and	
   pulse	
   intravenous	
  
methylprednisolone	
   for	
   4	
   days.	
   This	
   was	
   followed	
   by	
  
maintenance	
   immunosuppression	
   with	
   mycophenolate	
  
mofetil	
  and	
  tacrolimus.	
  
During a routine post-transplant follow-up visit, his
serum creatinine was found to have increased to 0.8mg/dl
from a baseline of 0.4mg/dl, prompting a biopsy that showed
a positive SV-40 stain. Immunosuppression was reduced by
withdrawal of mycophenolate mofetil and reduction in the
dose of tacrolimus to target trough levels of 4-5 ng/ml.
Viral clearance and improvement in graft function was
achieved with reduction in immunosuppression and monthly
IVIg (0.5 g/kg) therapy for 6 months. His graft function
however did not return to his previous baseline.
CASE 3
A 16-year-old Hispanic male who was an illegal
immigrant received a cadaveric kidney transplant due to end
stage renal disease secondary to nephronopthisis. Graft
function was excellent following induction with rabbit
Thymoglobulin and pulse steroid therapy. He was
maintained on a steroid free regimen consisting of tacrolimus
and mycophenolate mofetil. He developed acute rejection
due to missed doses of immunosuppressive medications that
resulted from insufficient funds to purchase medications. He
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was treated with Thymoglobulin and pulse steroid therapy
with recovery of function to his previous baseline of 0.9
mg/dl.
A few months later, he was found to have an elevation in
his serum creatinine. His serum creatinine peaked at 2.2
mg/dl. BK viremia was detected and his immunosuppression
was reduced. Initially the dose of mycophenolate mofetil
was reduced by 50% and with persistent viremia was
discontinued. The next step was a staged reduction in
tacrolimus dosing to target troughs of 4-5 ng/ml. With
persistent viremia, he received IVIg. Viral clearance was
seen after 5 monthly doses of 0.5g/kg with stabilization of
graft function and a decrease in serum creatinine to 1 mg/dl.
DISCUSSION
Pediatric renal transplant recipients are at high risk for
BK virus infection post transplant because they are more
likely to be naïve to the BK virus. Other risk factors include
HLA mismatch, the intensity of immunosuppression with an
increased incidence following treatment of rejection with
intensified immunosuppression using lymphocyte-depleting
therapy [10].
Prospective screening protocols have led to earlier
detection of BK viremia, which has helped minimize the
effect of BKVN on graft survival. Nonetheless, with
detection of BK viruria and viremia, there is insufficient
evidence to support additional therapy if there is an
inadequate response to reduction in immunosuppressive
therapy or in the face of established nephropathy.
Reduction in immunosuppression is accepted as the firstline management of BK viremia and nephropathy [2]. It has
been used as the sole therapy for BK viremia and
nephropathy [11]. The strategy for targeted reduction in
immunosuppression varies among transplant centers. The
most common approach involves decreasing and then
discontinuation of the anti-proliferative agent. The
calcineurin inhibitor is then decreased if viremia persists. In
a cohort study, Schaub et al. outlined their reduction
protocol, which initially involves reduction in calcineurin
therapy by targeting lower trough levels. This was done by
setting a lower tacrolimus trough than would be expected for
the post-transplant period i.e. targeting a trough of 6-8 ng/ml
instead of a trough of 8-10 ng/ml. If viremia persisted, the
calcineurin inhibitor was further reduced (eg the tacrolimus
trough levels were decreased from 6-8 to 4-6 ng/ml). The
final stage in the protocol was a sequential reduction in
mycophenolate moefetil dosing in increments of 50%. Using
this staged reduction protocol, viral clearance and
stabilization of graft function was seen with
immunosuppression reduction alone [11]. Reduction in
immunosuppression is however associated with an increased
incidence of acute rejection which has been reported in up to
25% of cases [12].
Reports have described the use of agents like cidofovir,
leflunomide, fluoroquinolones and IVIg with varied success
[3-5, 13, 14]. Cidofovir has anti-polyoma activities, which
has been demonstrated in in vitro experiments. It is however
extremely nephrotoxic which limits its use for management
of BKVN. It has also been associated with a recurrence of
BK viremia and persistent BKVN after an initial response
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[6]. Leflunomide has anti-viral properties against BK virus
and is an attractive option for treatment of BKVN since it
has minimal nephrotoxicity. It has been used successfully in
adult and pediatric transplant recipients in combination with
immunosuppression reduction [3, 13]. Fluoroquinolones
inhibits polyoma virus replication in vitro and has been
shown to decrease BK viral load. It has been used as a
prophylactic agent. Garbardi et al. demonstrated a
significantly lower incidence of BK viremia at 1 year in a
cohort of 160 patients who received fluoroquinolone therapy
for prophylaxis for at least 1 month post-transplant [5].
Case reports have emerged that have documented an
increase in BK viral load following administration of IVIg.
Boonyapredee M et al, reported their experience with a 57year old female renal transplant recipient who underwent a
biopsy for allograft dysfunction in the setting of BK viremia
8 weeks post-transplant. The histological findings were
consistent with Banff 1b acute cellular rejection and a
negative stain for SV-40 and negative C4d staining of
peritubular capillaries. The patient was given 2 g/kg of IVIg
with no adjustments to her baseline immunosuppression
since there was inadequate evidence to make a diagnosis of
BKVN. Her BK viral load increased exponentially after
administration of IVIg with a further increase in her serum
creatinine. A repeat biopsy revealed a positive SV-40 stain
within the epithelial cells of the tubules and moderate
tubulitis. Her immunosuppression was promptly decreased
and she received leflunomide for treatment of BKVN and a
steroid pulse for treatment of concurrent acute cellular
rejection. Her BK viral load decreased subsequently and
there was improvement in her graft function reported [8].
This finding is similar to a report by Maggiore et al. who
describes the case of a 49-year old woman who underwent a
renal biopsy when she presented with an elevation in her
serum creatinine up to 2.4mg/dl from a baseline of 1.6 - 1.8
mg/dl 14 months post-transplant. She was found to have
BKVN and immunosuppression was reduced and she
received 2g/kg of IVIg over 5 days. Her BK viral load was
closely monitored and observed to increase in the first week
following IVIg therapy from 7720 copies/ml to a peak of
144,440-copies/ ml after IVIg administration before a
progressive decline was seen over a 12-week period. Her
graft function showed gradual improvement with a decrease
in her serum creatinine to a new baseline of 2 mg/dl in the
29-month follow-up period [9].
IVIg has anti-inflammatory and BK neutralizing
properties demonstrated in in vitro experiments [15]. It has
been used for treatment of BKVN following an inadequate
response to reduction in immunosuppression and has been
reported to lead to a stabilization of allograft function,
clearance of viremia and histological resolution of BKVN [4,
14].
Reports exist on adult and pediatric transplant recipients
with BK viremia and nephropathy where IVIg was used with
improvement in renal function and significant graft survival
demonstrated. There was similarity in the dosing strategies
for IVIg in the reports of the largest adult and pediatric
cohorts [4, 14]. There reports provided some insight into the
utility of IVIg combined with immunosuppression reduction
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without the confounding effects of other therapeutic agents.
In the report by Sharma et al, stabilization of renal function
and histological resolution of BKVN was seen with IVIg
after recurrent BK viremia developed with discontinuation of
cidofovir therapy [6].
We utilized low dose IVIg treatments (0.5 g/kg) given
monthly over a 5 to 6 month period, which was similar to the
protocol described by Sharma et al. [6]. The most common
side effect seen was post infusion headache, which was
easily managed with acetaminophen. No case of acute
kidney injury was seen in our cohort as a result of IVIg
therapy. Our choice of low dose therapy distributed over a
period of time was based on the regimen used to treat other
post transplant viral infections. It was effective and led to
better inhibition of viral replication and better overall viral
eradication since viral clearance is usually slow in the face of
immunosuppression. Using low dose therapy also helped to
minimize the infusion related complications frequently seen
with high dose therapy.
Our findings highlight the effectiveness of IVIg as
second line therapy following a suboptimal response to
immunosuppression reduction and offer an alternative
therapy to the current management strategies. The optimal
dosing, frequency and duration of therapy needs to be
determined. Also, the indication for treatment, cost
effectiveness, availability and side effect profile require
further study.
The fact that the histological features of BKVN on light
microscopy are often difficult to distinguish from acute
cellular rejection and BKVN sometimes coexist with
rejection makes IVIg an attractive alternative strategy. Its
anti-BK attributes together with the anti-rejection effects
make it a unique therapeutic option in protecting against
rejection, which can occur following reduction of
immunosuppression. It is also the ideal treatment when the
diagnosis is unclear or while awaiting results of the SV-40
staining for the BK virus.
Despite being expensive and in limited supply, IVIg is an
appealing therapeutic option for the rising threat of BK
viremia and BKVN in the setting of less well-defined
options. Further study is needed to compare its efficacy to
the other management options and longer follow-up is
required to evaluate long-term benefits and graft survival.
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